Abstract
The goal of this chapter is to present several lines of evidence as to the importance of tumor site selection in oncology drug development. Tumor-host interactions differ according to the anatomical location of the tumor and can alter the pharmacodynamic effects of a drug candidate. In some instances, failure of a promising new drug to exhibit efficacy is attributed to drug resistance when instead, the lack of efficacy is a consequence of poor model characterization and selection. Orthotopic models are now presenting us with more-complex models to evaluate the activity of novel drug candidates. We present examples that demonstrate how implant site influences tumor growth kinetics and behavior; as a consequence of these influences, our interpretation of result with early stage drug candidates must be carefully considered.
In this chapter, we review a number of studies that support the notion that tumor implantation site represents a critical determinant for the successful and meaningful efficacy evaluation of chemotherapeutic agents.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 835:1–35.
Rawlins, M D. Cutting the cost of drug development. Nat Rev Drug Disc 2004; 3:360–364.
Schuh JCL. Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol 2004; 32:53–66.
Bibby MC. Orthotopic models of cancer for preclinical evaluation: advantages and disadvantages. Eur J Cancer 2004; 40:852–857.
Killion JJ, Radinsky R, Fiddler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1999; 17:279–284.
Kelland LR. "e;Of mice and men"e;: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004; 40:827–836.
Kerbel RS. What is the optimal rodent model for anti-tumor drug testing. Cancer Metastasis Rev 1999; 17:301–304.
Naito S, von Eschenbach AC, Fidler IJ. Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs in nude mice. J Natl Cancer Inst 1987; 78:377–385.
Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984; 44:3522–3529.
Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1:571–573.
Keyes KA, Mann L, Teicher B, Alvarez E. Site-dependent angiogenic cytokine production in human tumor xenografts. Cytokine 2003; 21:98–104.
Onn A. Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in mice. Clin Cancer Res 2003; 9:5532–5539.
Farre L, Casanova I, Guerrero S, Trias M, Capella G, Mangues R. Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model. FASEB J 2002; 16:975–982.
Fu X., Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopic ally from histologically intact patient specimens. Proc Natl Acad Sci USA 1992; 89:5645–5649.
Hoffman RM. Orthotopic metastatic models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999; 17:343–359.
Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M. A novel red fluorescent protein orthotopic pancreatic model for the preclinical evaluation of chemotherapeutics. J Surg Res 2003; 113:151–160.
Pesce A, Blubel HC, DiPersio L, Michael JG. Human lactic dehydrogenase as a marker for human tumor cells grown in athymic mice. Cancer Res 1977; 37:1998–2003.
Shih I-M, Torrance C, Sokoll LJ, Chan DW, Kinzler KW. Vogelstein B. Assessing tumors in living animals through measurement of urinary b-human chorionic gonadotropin. Nat Med 2000; 6:711–714.
Teicher B A, Herman TS, Holden SA, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990; 247(4949 Pt 1): 1457–1461.
Harrison S. Perspective on the history of tumor models. In: Teicher BA, ed. Tumor models in cancer research. Totowa: Humana Press, 2002:3–22.
Kidd JW, Rous P. A transplantable rabbit carcinoma originating in a virus-induced papilloma and containing the virus is masked or altered form. J Exp Med 1940; 71:813–837.
Doppelt SH, Slovik DM, Neer RM, Nolan J, Zusman RM, Potts JT. Gut-mediated hypercalcemia in rabbits bearing VX2 carcinoma: new mechanism for tumor-induced hypercalcemia. Proc Natl Acad Sci USA 1982; 79:640–644.
Shilling T.In vivo models ofhypercalcemiaofmalignancy.RecentResults Cancer Res 1994; 137:4475.
Hubbard WC, Hough AJ, Johnson RM, Oates JA. The site of VX2 tumor transplantation affects the development of hypercalcemia in rabbits. Prostaglandins 1980; 19:881–889.
Malave I, Blanca I, Fuji H. Influence of inoculation site on development of the Lewis lung carcinoma and suppressor cell activity in syngeneic mice. J Natl Cancer Inst 1979; 62:83–88.
Hill SA, Denekamp J. Site dependent response of tumours to combined heat and radiation. British J Radiol 1982; 55:905–912.
Keyes KA, Mann L, Cox K, Treadway P, Iversen P, Chen Y, Teicher B A. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex multiplex technology. Cancer Chemother Pharmacol 2003; 51:321–327.
Keyes KA, Mann L, Teicher B A, Alvarez E. Site-dependent angiogenic cytokine production in human tumor xenografts. Cytokine 2003; 21: 98–104.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Arjona, A.A., Alvarez, E. (2006). Tumor Site Implantation and Animal Model Selection in Oncology. In: Teicher, B.A. (eds) Cancer Drug Resistance. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-035-5_8
Download citation
DOI: https://doi.org/10.1007/978-1-59745-035-5_8
Publisher Name: Humana Press
Print ISBN: 978-1-58829-530-9
Online ISBN: 978-1-59745-035-5
eBook Packages: MedicineMedicine (R0)